RU99118510A

RU99118510A - COMPOSITION FOR THE TREATMENT OR PREVENTION OF PROSTATE CANCER

Info

Publication number: RU99118510A
Application number: RU99118510/14A
Authority: RU
Inventors: Коити Кодзима; Томово КОБАЯСИ
Original assignee: Санкио Компани, Лимитед
Priority date: 1997-02-26
Filing date: 1998-02-26
Publication date: 2001-06-10

Claims

1. Composition for treating or preventing prostate cancer, containing as an active ingredient a compound of formula I:

where R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a lower alkoxy group,
or its pharmacologically acceptable salt or other derivative of the compounds indicated.

2. Composition for treating or preventing prostate cancer under item 1, characterized in that it contains as an active ingredient a compound of formula I, where R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group or a lower group alkoxy, or its pharmacologically acceptable salt or other derivative of this compound.

3. A composition for treating or preventing prostate cancer according to claim 1, characterized in that the compound of formula I is N- [1-methyl-1- (4-methoxyphenyl) ethyl] -3-oxo-4-aa-5α- androst-1-ene-17β-carboxamide.

4. Composition for the treatment or prevention of prostate cancer according to any one of paragraphs. 1 to 3, characterized in that the composition is a form suitable for oral administration.

5. The use of the compounds of formula I:

where R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a lower alkoxy group, or a pharmacologically acceptable salt thereof or another derivative of said compound for the manufacture of a pharmaceutical composition for treating or preventing prostate cancer.

6. The use according to claim 5, wherein a compound of the formula I is used, where R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group or a lower alkoxy group, or a pharmacologically acceptable salt thereof or another derivative of said compound.

7. The use according to claim 5, wherein the compound of formula I is N- [1-methyl-1- (4-methoxyphenyl) ethyl] -3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide .

8. The use according to any one of paragraphs. 5 to 7, where the above-mentioned pharmaceutical composition is a form, acceptable oral administration.

9. A method of treating or preventing prostate cancer, comprising administering to a warm-blooded animal when such treatment is necessary and preventing an effective amount of an anti-cancer agent to treat prostate cancer, where the above agent is a compound of formula I, or its pharmacologically acceptable salt or other derivative of said compound

where R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group, a protected hydroxyl group or a lower alkoxy group.

10. The method according to claim 9, wherein R ¹ and R ² are the same or different, and each represents a hydrogen atom, a hydroxyl group or a lower alkoxy group.

11. The method according to claim 9, wherein the compound of formula I is N- [1-methyl-1- (4-methoxyphenyl) ethyl] -3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide . 12. A method according to any one of claims. 9 to 11, where the compound of formula I or its pharmacologically acceptable salt or other derivative of the compounds indicated is administered orally.